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This study investigated the therapeutic effects of interleukin (IL)-2 and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) co-administrated with antibacterial agents isoniazid (INH) and rifampin (RIF) to treat a mouse model of tuberculo-
sis (TB) infection. A drug-susceptible TB strain, H37Rv was used to infect mice and the effectiveness of IL-2 and GM-CSF 
was initially evaluated based on survival rate, bacterial counts in lungs and spleens and the pathological condition of the lungs. 
Next, the therapeutic effect of the immunotherapy regimen was assessed in multidrug-resistant strain OB35-infected mice. In 
the H37Rv infection model, IL-2 and GM-CSF monotherapies reduced bacterial numbers in the lungs by 0.82 (P<0.01) and 
0.58 (P<0.05) lg colony-forming units (CFU), respectively, and in the spleens by 1.42 (P<0.01) and 1.22 (P<0.01) lg CFU,
 re-
spectively, compared with the untreated group. Mice receiving immunotherapy developed fewer lesions in the lungs compared 
with mice receiving antibacterial therapy alone. In the OB35 infection model, immunotherapy with either cytokine resulted in a 
significant reduction of bacterial load in the lungs and spleens and less severe lesions in the lungs compared with the untreated 
or antibacterial therapy treated mice. Notably, mice receiving immunotherapy with both cytokines had a 30% survival rate 
which was higher than that in other treated groups, and had significantly less CFUs in the lungs and spleens (1.02 and 1.34 lg 
CFU) compared with antibacterial therapy alone (P<0.01). This study demonstrated that immunotherapy with both IL-2 and 
GM-CSF may be useful to treat multidrug resistant tuberculosis (MDR-TB). 
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Tuberculosis (TB) remains a major public health problem 
worldwide [1,2]. Directly Observed Therapy–Short Course 
(DOTS) is the main TB control strategy recommended by 
the World Health Organization and has been used for many 
years. DOTS, when used properly, can treat 95% of drug-     
susceptible TB cases. However, the prevalence of multidrug 
resistant (MDR) and extensively drug-resistant (XDR)-TB 
and Mycobacterium tuberculosis/HIV co-infection make it 
more difficult to control TB using the DOTS strategy alone. 
Moreover, drug-drug interactions cause significant prob-
lems in M. tuberculosis/HIV co-infected patients. Despite 
the use of second-line drugs, the side effects and cost mean 
the rational design of new treatment regimens is required to 
shorten the therapeutic period, and provide a more effica-
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cious treatment for MDR and XDR-TB, and TB in 
HIV-positive individuals [3]. 
Novel adjunctive immunotherapy using immunomodula-
tors can control infectious diseases [4]. Enhancing the im-
mune response of the host may protect the body against 
invasive bacteria and help to reduce drug resistance. M. 
tuberculosis is the causative agent of TB and preferentially 
infects macrophages as their host cells. The pathogenesis of 
tuberculosis involves a dynamic interaction between host 
and pathogen. Cytokines, immune cells and antibodies are 
important in sustaining a successful host defense against TB 
[5–7]. Numerous studies have demonstrated the treatment 
potential of cytokines in experimental and clinical studies. 
GM-CSF and IL-2 are immunomodulators that have been 
widely used for the treatment of other diseases. GM-CSF 
and IL-2 stimulate the immune system of the host by acti-
vating immune cells. GM-CSF induces the differentiation of 
circulating monocytes into certain types of macrophage in 
vivo. Activated macrophages act as effector cells in host 
defense by engulfing and killing M. tuberculosis and pre-
senting bacterial antigens to T cells. Stimulation with 
GM-CSF in vitro increases phagocytosis by macrophages 
and inhibits mycobacterial growth in macrophages [8,9]. 
IL-2 is a Th1 cytokine and is essential for the development 
of cell-mediated immune responses to intracellular patho-
gens [10]. Homeostasis of the Th1/Th2 response is likely 
associated with the progression of disease. Often Th1 re-
sponses are not present in TB patients with advanced dis-
ease [11,12]. Clinical trials demonstrated that IL-2 produc-
tion was reduced in MDR-TB patients [13]. Therefore, ex-
ogenous GM-CSF and IL-2 may provide a microenviron-
ment that enhances the activation of effector cells and pro-
motes Th1 response in vivo.  
Previous studies showed that IL-2 or GM-CSF and their 
delivery by DNA vaccine could enhance the efficacy of 
treatments for M. tuberculosis infection [14–19]. However, 
most studies used a drug-susceptible TB strain with a single 
cytokine treatment. In this study, we used recombinant IL-2 
and GM-CSF proteins directly as immunotherapeutic agents 
in combination with the first-line antibacterial drugs isonia-
zid (INH) and rifampin (RIF) to treat both drug-susceptible 
and multidrug-resistant TB. We assessed the efficacy of 
cytokine monotherapy and combination immunotherapy. 
We found either cytokine could enhance the therapeutic 
effects of INH and RIF in drug-susceptible M. tuberculosis 
infection and observed novel synergistic effects of IL-2 and 
GM-CSF in MDR-TB control.  
1  Materials and methods 
1.1  Antibacterial agents and cytokines 
INH and RIF were purchased from Red Flag Pharmacy in 
Shenyang, China. Lyophilized recombinant IL-2 and 
GM-CSF were kindly provided by Amoytop Biotech, Xia-
men, China. The cytokines were prepared in 0.9% sterile 
saline every two days and were stored at 4°C before use. 
1.2  Mice 
Specific pathogen-free female C57BL/6 mice aged 68 
weeks purchased from Vital River Co., Ltd., Beijing, China 
were maintained under barrier conditions in the Animal 
Biosafety Level-III Laboratory (ABSL-III) of Wuhan Uni-
versity, China and were fed a sterile commercial mouse 
diet. 
1.3  M. tuberculosis strains 
M. tuberculosis laboratory strain H37Rv (ATCC 93009) and 
multi-drug resistant strain OB35 displaying resistance to 
both INH and RIF in vitro were provided by Wuhan Uni-
versity. The minimum inhibitory concentration of INH and 
RIF for the OB35 strain was 1 g mL1 and 50 g mL1, 
respectively, as previously described [20]. Both bacterial 
strains were subcultured in Middlebrook 7H9-ADC (Becton 
Dickinson) medium for 10 d at 37°C. Bacteria were col-
lected by centrifugation and were washed with PBS, resus-
pended in sterile saline, and stored at 80°C until use.  
1.4  Infection of mice 
The CFU count of the bacterial suspension was determined 
using Middlebrook 7H10-OADC (Becton Dickinson) agar 
plates before mouse inoculation. Mice were infected intra-
venously via tail vein injection with 0.2 mL of bacterial 
suspension containing approximately 2×106 CFU M. tuber-
culosis H37Rv or OB35 [21].  
1.5  Treatment of drug-susceptible H37Rv and MDR-TB 
OB35 infection  
Following infection with M. tuberculosis H37Rv, mice were 
divided randomly into 6 groups (Table 1). Each experi-
mental group contained 5 mice. Five healthy mice were 
maintained in a non-infection room as healthy controls. On 
day 14 after infection, 5 mice from the untreated group were 
sacrificed to verify the pretreatment CFU counts in the 
lungs and spleens. Treatment was initiated on day 15 after 
infection and lasted 4 weeks. Each regimen was adminis-
tered once a day 5 days per week. RIF was dissolved in 
sterile feeding water at a final concentration of 0.1 g L1. 
Each mouse drank approximately 2 mL of water per day. 
The other drugs were dissolved in sterile saline in a total 
volume of 100 L and were administered via intramuscular 
injection. The doses of these drugs were as follows: INH 5 
mg kg1, IL-2 5000 IU/mouse, and GM-CSF 5000 IU/ 
mouse. In the untreated control group, 100 μL of sterile  
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IL-2 5  HRa) 10 
GM-CSF 5  HR+IL-2 10 
HRa) 5  HR+GM-CSF 10 
HR+IL-2 5  HR+IL-2+GM-CSF 10 
HR+GM-CSF 5  Untreated 15 
Untreated 10    
a) HR, isoniazid (INH) and rifampin (RIF). 
 
 
saline was used as a placebo. Mortality and body weights 
were monitored throughout the experiment, and the spleen 
from each mouse was weighed after sacrifice. Surviving 
mice were sacrificed within 1 week after termination of the 
treatment. The in vivo study was repeated twice.  
Following analysis of results from treatment of the 
H37Rv infection model, only regimens of INH-RIF (HR) in 
combination with IL-2 or GM-CSF or both cytokines were 
adopted in the OB35 infection model in addition to antibac-
terial therapy and saline (Table 1). All treatment parameters 
were the same as for treatment of the H37Rv infection. 
1.6  Bacterial counts 
Portions of the lung and the whole spleen from each mouse 
were removed during autopsy and were weighed before 
homogenization in sterile saline. The tissue suspension was 
serially diluted 10-fold, and 0.1 mL of each dilution was 
plated in triplicate onto Lowenstein-Jensen medium and 
incubated at 37°C for 4 weeks [22]. Bacterial colonies were 
enumerated, and the results were expressed as lg CFU per 
gram of the organs.  
1.7  Histopathology 
The remaining portions of the lungs were fixed in 10% neu-
tral formaldehyde, and after dehydration, transparent, wax-
ing, embedding, and slicing, the tissue sections were pre-
pared. The sections were stained with hematoxylin and eo-
sin and were analyzed by a certified pathologist [21,23]. 
Additionally, acid-fast staining was performed as previously 
described for the visual observation of mycobacteria in the 
lungs [24,25]. 
1.8  Statistical analysis 
Data were expressed as the mean plus standard deviations. 
Statistical significance between each group was analyzed by 
Kaplan-Meier survival analysis with Log-rank test, 
ANOVA and t-test using Prism statistical software program. 
P<0.05 was considered to be statistically significant.  
2  Results 
2.1  Efficacy of treatment in the H37Rv infection model 
2.1.1  Survival rate and mean spleen weight 
In the saline control group, 1 mouse (1/5) died at week 6 
post-infection, and the rest were severely sick. All the 
treated mice survived until the end of the experiment. As 
shown in Figure 1, after 4 weeks of treatment the mean 
spleen weight of mice receiving HR or HR plus a single 
cytokine combination regimen was significantly reduced 
compared with the untreated group. However, no difference 
in mean spleen weight was observed between mice treated 
with HR or immunotherapy regimens alone. For mice re-
ceiving either cytokine alone, spleen weights were the same 
as those of untreated mice. 
2.1.2  Measurement of CFU in the lungs and spleens 
The bacterial burden in the lungs and spleens from each 
group was determined after 4 weeks of incubation on cul-
ture plates. Overall, bacterial numbers in all HR treated 
groups, single cytokine treated groups and HR plus 
IL-2/GM-CSF treated groups were significantly reduced 
compared with the early or late saline treated control groups. 
HR significantly inhibited bacterial growth in lungs and 
spleens. Bacterial numbers in lungs and spleens were re-
duced by at least 1 lg CFU after antibacterial therapy or 
immunotherapy with HR plus IL-2 or GM-CSF (Table 2). 
When compared with the late untreated group, IL-2 and 
GM-CSF monotherapy regimens reduced the bacterial 
number in the lungs by 0.82 (P<0.01) and 0.58 (P<0.05) lg 
CFU, respectively, and in the spleens by 1.42 (P<0.01) and 
1.22 (P<0.01) lg CFU, respectively (Table 2). Given that the 
two cytokines are not bactericidal, the reduction of the bac-
terial loads was likely due to the enhanced host protective 
immune response. However, reduced CFU in the immuno- 
 
 
Figure 1  Mean±SD weight of spleens from mice infected with H37Rv M. 
tuberculosis on day 42 post-infection. 
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therapy groups were not statistically significant when  
compared with the antibacterial therapy group (P>0.05) 
(Table 2).  
2.1.3  Histopathological examination  
Lungs from the untreated control group exhibited severe 
lesions (Figure 2A). Alveolar structural damage and the 
infiltration of numerous mononuclear phagocytes were also 
observed in the untreated control group. Lungs from the 
IL-2 and GM-CSF monotherapy groups had fewer lesions, 
consistent with the CFU data (Figure 2B and C). Mice re-
ceiving HR+IL-2 or GM-CSF exhibited no apparent lesions 
(Figure 2D and E). Although differences in the CFU counts 
between the antibacterial therapy and cytokine-assisted 
immunotherapy groups were not significant, lungs from the 
cytokine-assisted immunotherapy groups displayed fewer 
lesions or were close to normal in appearance (Figure 
2D–G). The histopathological results suggested that exoge-
nous cytokine treatment could accelerate the recovery of 
hosts from TB.  
Table 2  CFU counts in the lungs and spleens of mice infected with the 
H37Rv strain after 4 weeks of treatmenta) 
Treatment 
Lg CFU/g organ (mean±SD) 
Lung on day 
14 
Lung on day 
43 
Spleen on day 
14 
Spleen on day 
43 
Untreated 7.44±0.39 7.60±0.22 6.68±0.25 7.76±0.17 
IL-2  6.78±0.05**  6.34±0.13** 
GM-CSF  7.02±0.15*  6.54±0.13** 
HR+IL-2  6.34±0.08**  5.75±0.12** 
HR+GM-CSF  6.09±0.08**  5.90±0.06* 
HR  6.18±0.18**  5.92±0.13** 
a) Significant differences were observed between all treated groups and 
the untreated control group; *, P<0.05; **, P<0.01. No significant differ-
ence was observed between the HR+IL-2, HR+GM-CSF and HR groups. 
CFU, colony-forming units; HR, isoniazid (INH) and rifampin (RIF). 
 
 
Figure 2  Histopathology of lung sections from mice infected with 
H37Rv M. tuberculosis on day 42 post-infection. A, Untreated control. B, 
IL-2. C, GM-CSF. D, HR+IL-2. E, HR+GM-CSF. F, HR. G, Healthy con- 
trol (shown at 100× magnification). 
2.2  Efficacy of treatment in the multidrug-resistant 
strain OB35 infection model 
2.2.1  Survival rate and mean body weights 
Eight untreated mice (8/10) rapidly died within 25 days 
post-infection. All untreated mice had died by the end of the 
experiment (Figure 3A). In contrast, up to 25 days 
post-infection, 3 mice (3/10) in each of the HR and HR+IL- 
2+GM-CSF groups and 6 mice (6/10) in the HR+IL-2 group 
died, whereas only 1 mouse (1/10) died in the HR+GM-CSF 
group (Figure 3A). However, most of the treated mice died 
three weeks after treatment. By the end of the treatment, 3 
(3/10) mice in the HR+IL-2+GM-CSF group and 1 (1/10) 
mouse in each of the HR and HR+IL-2 groups survived 
(Figure 3A). Analysis of the survival curves by log-rank test 
demonstrated that HR+GM-CSF and HR+IL-2+GM-CSF 
survival was statistically significant from the untreated 
group (P<0.05). The results suggested that administration of 
antibacterial drugs combined with single cytokine regimens 
protected the host from early death, whereas a regimen 
containing drug treatment plus both cytokines reduced the 
mortality rate of the MDR-TB infection and prolonged sur-
vival. 
The mean body weight of mice from each group was 
monitored as an indicator of disease progression. All in-
fected mice exhibited similar weight loss 2 weeks after in-
fection. After the second week of treatment, the weight of 
mice receiving HR or HR+IL-2 or GM-CSF treatment sta-
bilized. In contrast, mice receiving HR+IL-2+GM-CSF ex-
hibited significant weight gain at the same time point. All 
treated mice gained weight gradually during the entire 
course of treatment (Figure 3B). Although the mice receiv-
ing HR exhibited weight gain, the mean body weight curve 
of the HR group was below that of the others, which sug-
gested that HR treatment alone was less effective for host 
recovery. Moreover, the mean body weight curve in the 
HR+IL-2+GM-CSF group was above that of the other 
treatment groups, which also suggested that the regimen of 
HR plus both cytokines was the most efficacious treatment 
in terms of weight gain. 
2.2.2  Measurement of CFU in the lungs and spleens 
After treatment, bacterial counts from the lungs and spleens 
of all 10 mice per group, including dead and surviving mice 
were measured. As shown in Table 3, all the immunothera-
py regimens significantly inhibited the growth of multi-
drug-resistant M. tuberculosis in the lungs and spleens 
(P<0.01) compared with the early and late untreated groups. 
Although the bacterial loads in the lungs and spleens were 
reduced in the HR regimen compared with the late untreated 
group, HR did not appear to inhibit bacterial growth effi-
ciently in the lungs when compared with the CFU of the 
early untreated group. Co-administration of a single cyto-
kine and HR had greater efficacy than HR alone. The 
HR+IL-2 and HR+GM-CSF treatments resulted in a  
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Figure 3  Survival curves and weight loss of treated or untreated mice infected with OB35 M. tuberculosis. A, Kaplan-Meier survival curves for each group 
of treated mice (n=10). a, HR; b, HR+IL-2; c, HR+GM-CSF; d, HR+IL-2+GM-CSF. B, The mean body weight. 
Table 3  CFU counts in the lungs and spleens of mice infected with the OB35 strain after 4 weeks of treatmenta) 
Treatment 
Lg CFU/g organ (mean±SD) 
Lung on day 14 Lung on day 43 Spleen on day 14 Spleen on day 43 
Untreated 8.38±0.06 9.23±0.05 7.29±0.15 7.97±0.03 
HR  8.78±0.08##  6.70±0.06## 
HR+IL-2  8.11±0.20**##  6.41±0.14**## 
HR+GM-CSF  8.05±0.39*#  6.46±0.14*## 
HR+IL-2+GM-CSF  7.76±0.33**##  5.36±0.23**## 
a) Significant differences were observed between the treated groups and the untreated group (#), or between the immunotherapy groups and HR group (*). 
#, P<0.05, ##, P<0.01; *, P<0.05, **, P<0.01. CFU, colony-forming units; HR, isoniazid (INH) and rifampin (RIF). 
 
greater reduction of CFU in lungs (0.67 and 0.73 lg CFU, 
respectively, P<0.01) and spleens (0.29 and 0.24 lg CFU, 
respectively, P<0.05) compared with HR alone. Moreover, 
HR+IL-2+GM-CSF treatment induced the greatest reduc-
tion of lung and spleen bacterial loads (1.02 and 1.34 lg 
CFU, respectively), when compared with HR (P<0.01).  
2.2.3  Histopathological examination of the lungs 
Histopathological results are shown in Figure 4. Extensive 
lung lesions and hyperemia congestion in the alveoli with 
damaged construction were observed in lung sections from 
untreated mice (Figure 4A). Antibacterial therapy did not 
result in a significant improvement although the pulmo-
nary bacterial loads decreased when compared with un-
treated mice (Figure 4A and B). The administration of HR 
plus single cytokine regimens resulted in clearer alveoli 
structures and fewer lesions (Figure 4C and D). In contrast, 
the HR+IL-2+GM-CSF regimen appeared to be the most 
efficacious treatment because the lesion area of the lungs 
from surviving mice in this group was greatly reduced  
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Figure 4  Histopathology of lung sections from treated or untreated mice 
infected with OB35 on day 42 post-infection. AF, Hematoxylin and eo-
sin-stained lung tissue sections (shown at 100× magnification). A, Un-
treated control. B, HR. C, HR+IL-2. D, HR+GM-CSF. E, HR+IL-2+GM- 
CSF. F, Healthy control. GL, Acid-fast stain of M. tuberculosis in lungs 
(shown at 400× magnification). G, Untreated control. H, HR. I, HR+IL-2.  
J, HR+GM-CSF. K, HR+IL-2+GM-CSF. L, Healthy control. 
(Figure 4E). Furthermore, we examined bacteria in the 
lungs of infected mice using acid-fast staining, and the re-
sults confirmed the CFU data from each matched group 
(Figure 4G–L).  
3  Discussion 
Disorders of cytokine networks are closely associated with 
disease [26,27]. Cytokines produced by immune cells can 
influence the outcome of mycobacterial infection. The aim 
of this study was to determine whether exogenous cytokines 
could improve the efficacy of first-line drugs during active 
M. tuberculosis infection.  
Using the M. tuberculosis H37Rv infection model, both 
IL-2 and GM-CSF alone reduced the bacterial load in the 
lungs and spleens of mice. The primary function of IL-2 is 
to stimulate the proliferation of T cells, whereas GM-CSF 
stimulates macrophage differentiation, proliferation, and 
activation, which can improve antigen-presenting efficiency. 
Both cytokines are important for eliciting a protective im-
mune response to M. tuberculosis infection. The bacterial 
inhibitory rates following either cytokine monotherapy were 
80% in the lungs and 90% in the spleens compared with 
the untreated group. The reduction of CFU in the absence of 
antibacterial drugs was likely due to cytokine-induced acti-
vation of host immunity. However, the therapeutic effects 
observed when using antibacterial drugs and a single cyto-
kine was not significant when compared with antibacterial 
drugs alone in terms of CFU and spleen weight. This may 
be due to the bactericidal effects of the HR regimen over-
whelming the host immune clearance of the bacteria, alt-
hough a relatively low dose of HR was intentionally used 
throughout the entire experiment. However, it was reported 
that specific cytokines had an essential protective role in 
preserving alveolar structure of M. tuberculosis infected 
mice [28]. 
Based on results using the H37Rv model, we investigated 
the effect of immunotherapy with IL-2 and/or GM-CSF in 
the MDR-TB model. Given the virulence of the OB35 strain, 
only the combination regimens were used for treating mice 
infected with M. tuberculosis OB35 strain. All the combina-
tion regimens prolonged the survival time and decreased the 
bacterial load of infected mice. Eight untreated mice (8/10) 
died rapidly between day 20 and day 25 because of the high 
virulence of the MDR-TB strain, whereas the number of 
mice that died in the treated group was less than 6, suggest-
ing that the combination regimens slowed disease progres-
sion after the initial treatment. The effects of immunothera-
py were revealed by further analysis. The use of combina-
tion HR and cytokine treatment further enhanced the inhib-
itory effect of the two antibacterial drugs in terms of CFU 
counts, in contrast to the H37Rv infection model. As a re-
sult, moderate numbers of lung lesions were observed in the 
cytokine-treated groups.  
Notably, the synergistic effect of IL-2 and GM-CSF was 
demonstrated clearly in the MDR-TB model as follows: (i) 
the most dramatic increase in mean body weight was ob-
served in mice treated with HR+IL-2+GM-CSF; (ii) the 
reduction of lung and spleen CFU counts under the HR+IL-     
2+GM-CSF regimen was one lg CFU greater than in the 
antibacterial therapy alone regimen, which demonstrated the 
advantage of the two cytokine combination immunotherapy; 
(iii) the synergistic effect of these cytokines prevented the 
formation of lesions in the lungs; and (iv) mice receiving 
the HR+IL-2+GM-CSF regimen had a higher survival rate 
and statistically significant survival curve compared with 
untreated mice. Indeed, the synergistic effect of IL-2 and 
GM-CSF in enhancing the immune response was also re-
ported in a vaccine study [29,30]. IL-2 stimulates the im-
mune response by activating effector cells, whereas 
GM-CSF enhances the immune response by increasing an-
tigen presentation through macrophages. The different 
mechanisms of these two cytokines in enhancing the host 
protective response may account for the synergistic effect 
observed when both cytokines with antibacterial drugs are 
used to treat MDR-TB. The results of the current study 
demonstrated that IL-2 and GM-CSF could improve the 
efficacy of anti-tuberculosis drugs leading to a significant 
decrease in the bacterial load. Therefore, the use of IL-2 and 
GM-CSF may be used to shorten the treatment duration and 
improve the treatment outcome for MDR-TB. It will be of 
interest to screen other cytokines to enhance the therapeutic 
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effect of TB drugs in future studies. 
However, there are limitations to this study. Because of 
its high virulence and high dose of infection, a high mortal-
ity rate was observed in the OB35-infected mice. A reduced 
infection dose, different doses of cytokines, and longer 
treatment duration will be tested in future studies to find a 
more significant efficacy of protection. As OB35 is resistant 
to both INH and RIF, other first-line or second-line drugs 
will be evaluated to assess the immunotherapeutic effects of 
cytokines.   
In summary, the use of IL-2 and/or GM-CSF as im-
munomodulators improved the efficacy of conventional 
antibacterial drugs in drug-sensitive and MDR-TB murine 
models. This study is the first report to describe the syner-
gistic effects of combined IL-2 and GM-CSF for MDR-TB 
treatment. The cytokine network is complex because of the 
synergism and suppression among different cytokines. Thus, 
further studies of the mechanisms involved and clinical data 
are needed to promote new opportunities for therapeutic 
intervention in TB. 
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